A strong FDA could pull molecular-diagnostics industry out of a rut

02/18/2014 | Xconomy

Molecular diagnostics have the potential to reduce waste and overtreatment while helping patients, but the field is stuck in a rut, Luke Timmerman writes. "The molecular diagnostics industry needs a tough, science-minded, credible regulator ... who can comb through complex data sets and say with confidence what's real, what's clinically meaningful" and what isn't, he writes. A lack of regulations on companion diagnostics fosters skepticism among payers and investors, Timmerman writes.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY